Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620852 · ClinicalTrials.gov registry record · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
A NA study of Breast Cancer and Breast Cancer Screening, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 100,000
- Enrollment target
- 11
- Study locations
NCT02620852 is a NA study of Breast Cancer and Breast Cancer Screening that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 100,000 participants, above the 2,722-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (3574% higher). The trial reports 11 study locations across 7 states.
The verdict
NCT02620852, a NA study of Breast Cancer and Breast Cancer Screening, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 100,000 participants
- Enrollment target
- 11
- Study locations
Study Summary
Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mammograms and biopsies. With the current screening approach, half of the women who undergo annual screening for ten years will have at least one false positive biopsy. Potentially more important are cancer diagnoses for growths that might never come to clinical attention if left alone (called "overdiagnosis"). This can lead to unnecessary treatment. Even more concerning is evidence that up to 20% of breast cancers detected today may fall into the category of "overdiagnosis." The WISDOM 1.0 study compares annual screening with a risk-based breast cancer screening schedule, based upon each woman's personal risk of breast cancer. The investigators have designed the study to be inclusive of all, so that even women who might be nervous about being randomly assigned to receive a particular type of care (a procedure that is typical in clinical studies) will still be able to participate by choosing the type of care they receive. For participants in the risk-based screening arm, each woman will receive a personal risk assessment that includes her family and medical history, breast density measurement and tests for genes (mutations and variations) linked to the development of breast cancer. Women who have the highest personal risk of developing breast cancer will receive more frequent screening, while women with a lower personal risk would receive less frequent screening. No woman will be screened less than is recommended by the USPSTF breast cancer screening guidelines. If this study
Conditions Studied
Interventions
- OTHER Complete a health questionnaire
- DEVICE Provide a saliva sample for genetic testing
- OTHER Screening advice based on a comprehensive risk assessment
- OTHER Screening advice based on a basic risk assessment
Study Locations (11)
California
- University of California Irvine - Irvine
- University of California Los Angeles - Los Angeles
- University of California Davis - Sacramento
- University of California San Diego - San Diego
- University of California San Francisco - San Francisco
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- TopLine MD Alliance - Miami
Illinois
- University of Chicago - Chicago
Louisiana
- Louisiana State University - New Orleans
New York
- Weill Cornell Medicine - New York
South Dakota
- Edith Sanford Breast Center - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2026-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02620852
The ClinicalTrials.gov registry entry for NCT02620852 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,722-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (3574% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Complete a health questionnaire is the first listed.
NCT02620852 reports 11 study locations spanning 7 distinct geographic areas - top geographies include California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT02620852 about?
NCT02620852 is a clinical study titled "Women Informed to Screen Depending on Measures of Risk (Wisdom Study)". Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early whe...
What is the current status of trial NCT02620852?
This trial is currently recruiting. It is a NA study. The enrollment target is 100,000 participants. The study started on 2016-08-31. Estimated completion is 2026-09-01.
What conditions does trial NCT02620852 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Cancer Screening, Breast Carcinoma in Situ.
What interventions are being tested in trial NCT02620852?
The interventions under investigation include: Complete a health questionnaire (OTHER), Provide a saliva sample for genetic testing (DEVICE), Screening advice based on a comprehensive risk assessment (OTHER), Screening advice based on a basic risk assessment (OTHER).
Who is sponsoring clinical trial NCT02620852?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02620852 being conducted?
This trial has 11 study locations across Alabama, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.